GNL3编排AR转录程序,以驱动抵抗割的前列腺癌和免疫逃避
Cuiting Zhang1,2,3,4, Tin Long Cheong1,2,3,4, Nitin Narwade1,2,3,4
1Cancer Centre, University of Macau, Taipa, Macau SAR, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 3, 2026
概括
基因核蛋白3 (GNL3) 是一种新型的雄激素受体 (AR) 核心调节器,用于割抵抗性前列腺癌 (CRPC). GNL3驱动瘤生长和免疫逃避,使其成为晚期前列腺癌的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 雄激素受体 (AR) 信号驱动割抵抗性前列腺癌 (CRPC).
- 在CRPC中AR信号的机制尚未完全理解.
- 鉴定新型AR同调剂对于理解CRPC进展至关重要.
研究的目的:
- 在CRPC中识别新的AR联合调节剂.
- 阐明GNL3在AR转录程序中的双重作用.
- 研究GNL3作为晚期前列腺癌的潜在治疗点.
主要方法:
- 对CRPC和原发性前列腺癌细胞的蛋白质基因分析.
- 评估GNL3与AR的相互作用及其对染色质占用量的影响.
- 分析GNL3对细胞增殖和免疫基因表达的影响.
- 评估GNL3对CRPC细胞对AR抗剂和瘤进展的敏感性的影响.
主要成果:
- 鉴定出G蛋白核状3 (GNL3) 是一种新型AR核心调节剂.
- GNL3增强了增殖基因的AR介导转录 (例如,NEK2,CDC20).
- GNL3通过HDAC抑制免疫反应基因 (例如CXCL10,TAP1),促进免疫逃避.
- 增加GLN3表达与前列腺癌的不良临床结果相关.
- 在GNL3 Knockdown中,它使CRPC细胞对AR抗体敏感,并减少瘤生长/转移.
结论:
- 在CRPC中,GNL3充当双重功能的AR辅调剂,促进CRPC中的增殖和免疫抑制.
- GNL3是晚期前列腺癌的一个有前途的治疗点.
- 对NEK2,HDAC和AR信号的组合抑制可能是CRPC的可行的治疗策略.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
相关概念视频
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:45Regulation of Nuclear Protein Sorting
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...